As of August 2008, the new instrument of a second opinion was introduced by the Federal Joint Committee (G-BA), comprising those pharmaceutical drugs that can be included in this process: primarily Orphan Drugs, highly effective new pharmaceutical drug therapies and procedures with higher costs or, which from the standpoint of the G-BA, involve higher risks, that are, e.g. used for the.